October 4th, 2016
Researchers are seeking ways to make prostate cancer biopsies safer.
While absolute rates of biopsy and post-biopsy complications have decreased after several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers.
The study is the largest to examine the impact of PSA screening trials and revised PSA screening guidelines on rates of prostate biopsy and the first to examine their impact on post-biopsy complications. The results, published in the March 2016 issue of European Urology, suggest a need to reduce the harm associated with biopsy.
September 27th, 2016
Surgeons find short breaks prove valuable in providing best care
Perfecting a skill requires equal parts natural talent, dedication and practice. A concert violinist plays a single piece of music over and over. A major league pitcher hurls strikes across home plate until the stadium lights go out. And a surgeon spends day after day leaning over an operating table while maintaining mental focus on the patient.
For all three, this kind of physical exertion and repetition stresses the body, leaving it vulnerable to work-related injuries that, over time, can cut careers short. [...]
September 13th, 2016
Clinical trials are the mechanism through which new and promising therapies for safe, effective cancer treatment ultimately become available.Â Not only do trials help identify new or best-practice therapeutic treatment options, but the act of participating in a trial has been shown to actually improve survival.
One of the most promising areas of research to fight cancer involves immunotherapy -- the use of vaccines or viruses as anti-cancer agents.Â Immunotherapeutic approaches through the use of vaccines, stimulates the bodyâs own cells to identify and fight cancer cells, utilizing a similar mechanism of action as we do with common childhood vaccines including measles, mumps and rubella (MMR). Viral therapies introduce a virus into [...]
September 13th, 2016
By Sara Tiner
Crumbling infrastructure puts us at risk, especially if itâs our own internal, bony frame.
But patients dealing with thinning bone in hips and spine have a choice to make.
They can accept the inevitable slumping spine and eventual hip fracture with all its associated disability that is quite likely to occur, or roll the dice with complications from osteoporosis medications.
Dr. KhoslaÂ isÂ one of the top osteoporosis experts in the world and a past president of the American Society for [...]
September 8th, 2016
Makshita "Maks" Luthra is a Master of Public Health candidate specializing in Public Health Administration & Policy, a Graduate Research Assistant at the University of Minnesota, and an associate health services analystÂ in theÂ Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.Â
Childhood obesity has more than doubled in children and quadrupled in adolescents in the past 30 years. It is often linked to unhealthy eating habits and sedentary lifestyle. Another significant factor associated with obesity in children and adolescents are âadverse childhood experiences,â or ACEs. ACEs are [...]
September 2nd, 2016
By Sara Tiner
But is the current survey deluge training us to ignore the ones that actually matter? Ask Ann Harris, associate director of Mayo Clinicâs Survey Research Center, and sheâll nod.
âNow everyone has a survey,â she says. âI think we've just over-surveyed people and our challenge coming up is how do we do this?â
Mayo Clinic sends thousands of surveys a year to patients.
They flow out over the internet of course, but also by phone and (snail) mail. But the surveys donât flow back in [...]
August 16th, 2016
10,000 people help answer a basic individualized medicine question
Nearly 1 out of every 3 American adults has high blood pressure. About 70 percent of them take medication for their condition, but only half have it under control. Why? The answer gets to the heart of individualized medicine: Because each person has a unique genetic makeup, everyone responds differently to drugs.
In recent years, individualized medicine, sometimes called precision medicine, has made headlines by predicting the possibility an individual may develop a specific disease [...]
August 10th, 2016
In 2012, Rochester Epidemiology Project (REP) co-directors Walter Rocca, M.D., Mayo Clinic; and Barbara Yawn, M.D., Olmsted Medical Center; and their colleagues, published a paper describing the generalizability of epidemiological findings from one population to others.
Their premise - health and health care information derived from the largely ethnically homogeneous population in Olmsted County, Minnesota, and more recently in the 27 counties that comprise the REP, can indeed impact our ability to provide better care â regionally, nationally and beyond.
âWe suffer from the Lake Wobegon effect,â laments Dr. Rocca. âPeople say, âah yes, Minnesota, the place where all women are strong, all men are good looking, all children are above average, and you have a lot of cornfields â but what could you possibly tell me about my much more diverse population?ââ [...]
August 4th, 2016
Informed consent made easier in pediatric emergency sedation
The science of health care delivery can be very exciting â sometimes offering a futuristic peak into the way things could be. Soon we may have an app that enables near instantaneous health data analysis and distillation, and brings individualized care suggestions to a providerâs fingertips. Crunching data from hundreds of thousands of patients, finding the ones that are most like the patient in front of the provider, adding in genetic information, personal preferences and more, and in a blink of an eye, giving information for the most efficient and effective care.
In the meantime, we do things a little more manually, but the end, results are similar. [...]
August 3rd, 2016
By Bob Nellis
The core group of Mayo Clinic researchers thatÂ moved their lab to the base camp at Mount Everest to study heart disease and aging are at it again, this time in Africa. Along with a party of nearly 35, they will be climbing Mt. Kilimanjaro, obtaining scientific data from the climbers along the way.
Led by Mayo physiologist Bruce Johnson, Ph.D. and joined by Amine Issa, Ph.D., Courtney Wheatley, Ph.D., and Jan Stepanek, M.D., among others, the group will monitor climbersâ heart rates, oxygen saturation, movement, energy expenditure, skin temperature and the quality of their sleep. Theyâll also conduct ultrasound scanning to determine differences in younger and older climbers as they react to the altitude.
July 26th, 2016
By Sara Tiner
But the costs associated with bringing a drug from idea to market run into the billions, making drug companies highly risk averse. And in the academic world, timelines or project shifts can slow down discovery, limiting the innovative potential of academic research.
Regardless, patients still need medical advances now, as well as a pipeline of innovation to improve treatment in the future.
Thomas âTCâ Chung, Ph.D., associate director of the Mayo Clinic Center for Clinical and Translational Science (CCaTS) Office of Translation to Practice (OTP) at Mayo Clinic, has worked in both the academic and pharmaceutical worlds. Now he and the OTP help [...]
July 22nd, 2016
Join us October 20, in Phoenix, at the 2016 Arizona Health Equity Conference.
A statewide event in its third year, the conference will highlight health equity research, practice and policy efforts taking place in Arizona. Mayo Clinic is the lead organizer and sponsor of the conference, which enables attendees to facilitate innovative collaborations.
The theme of the conference is "Building Bridges: Connecting Communities in Research, Practice and Policy."
Attendees include physicians, nurses, researchers, clinicians, public health professionals, community health workers and social workers.
Proposals for presentations and posters can be submitted through Aug. 12. All presentations and posters must be related to health equity to be [...]
July 5th, 2016
âNever go to the hospital in July,â a phrase often repeated by patients; and perpetuated by a myriad of hospital employees, casts a worrisome tone over care received in July. Thus we hear of the âJuly Phenomenon.â
This is because each July 1 is the start of the medical residency year. A day full of mixed emotions: Â excitement, splendor, fear, stress, and accomplishment; it is the very environment that many clinicians thrive in. It also starts the period that some people fear can be very distracting for new doctors, and possibly even dangerous for their patients. [...]
June 24th, 2016
The Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery has a booth (#211) at theÂ AcademyHealth Annual Research Meeting June 25-28 in Boston. Â If youÂ happenÂ to be there, stop by for a visit. You'll be able to learn more about all kinds of health services research going on at Mayo Clinic, although this year much of the conversation will revolve around epidemiology and population health.
We'll be sharing some information about the Rochester Epidemiology Project too, which is celebrating 50 years of continuous National Institutes of Health funding this year. Lots of potentialÂ research projectsÂ in this unique national resource, which has led to more [...]
June 16th, 2016
It has been 50 years since Leonard Kurland, M.D., successfully obtained funding from the National Institutes of Health to start the regional collaboration and medical records-linkage system known as the Rochester Epidemiology Project (REP).
This unique national resource was made possible because of the collegial relations of the health care providers in Rochester, Minnesota, at the time. The initial medical records and the data sharing and data mining capabilities were established by the Mayo brothers as part of their pioneering idea of a group practice and their shared education mindset. Henry Plummer, M.D., Mabel Root, and Joseph Berkson, M.D., icons of Mayo Clinic history, led [...]
June 15th, 2016
The Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery is pleased to welcome four new scholars to the Kern Health Care Delivery Scholars Program.
Elizabeth Lorenz, M.D. â Nephrology and Hypertension
Oliver Tobin, M.B.,B.Ch., BAO, Ph.D. â Neurology
June 7th, 2016
By Bob Nellis
From Taiwan to Texas, anyone who has anything to do with biosciences is here in San Francisco to hear speakers, attend education sessions, but mostly to network and make contacts for business and research. Mayo Clinic is here along with Destination Medical Center in Minnesota to talk about our research activities and make a major announcement later today. Mayo's research centers are represented in the Minnesota Pavilion at the conference and by several of our scientists and leaders.
We are spreading the word about Mayo being the NIHâs pick for the national biobank . It was announced [...]
May 31st, 2016
By Bob Nellis
On May 17, 2016, the U.S. Food and Drug Administration granted accelerated approval to nivolumab (OpdivoÂŽ) for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation.
Nivolumab also received a breakthrough therapy designation for the treatment of relapsed or refractory cHL after failure of autologous HSCT and brentuximab vedotin. Nivolumab also has orphan drug status for the treatment of Hodgkinâs lymphoma under FDA's accelerated approval program.
Much of the credit for these achievements is due to the work of Stephen Ansell, M.D., Ph.D. of Mayo Clinic. Dr. Ansell led a multi-institution phase I clinical trial of nivolumab which found the immune-boosting drug [...]
May 3rd, 2016
Determining which drug works better for which patients
"Our findings definitely point toward important age-related risk that merits consideration when doctors are making treatment recommendations," says lead author Neena S. Abraham, M.D.
To the average TV viewer, it may seem like new drugs flood the marketplace daily.However, from the 1950s until just recently, warfarin was the only available anticoagulant drug approved by the Food and Drug Administration (FDA) to prevent blood clotting. One of the most common reasons people take an anticoagulant is to reduce stroke and heart attack risk related to atrial fibrillation, an irregular and often rapid heart rate that commonly causes poor blood flow. [...]
April 12th, 2016
The Human Papillomavirus (HPV) is the most common sexually transmitted disease (STD), with about 14 million new cases each year.
Surprisingly, this STD is largely asymptomatic but can carry quite a punch.Â HPV affects both men and women and can cause cervical cancer and other cancers of the genitals, anus, mouth, and throat, all of which can lead to severe disease, disability, infertility or death.
There are currently three different licensed vaccine options for use in girls and boys that protect against and prevent HPV, and using these vaccines routinely could potentially prevent 70% - 90% of cervical [...]